Abstract
Therapeutic development in Parkinson's disease is hampered by the paucity of well-validated biomarkers that can assist with diagnosis and/or tracking the progression of the disease. Since its inception, the Michael J Fox Foundation for Parkinson's Research has invested heavily in biomarker research and continues to prioritize discovery and development efforts. This article summarizes the history and evolution of the Michael J Fox Foundation's role in supporting biomarker research and lays out the current challenges in successfully developing markers that can be used to test therapies, while also providing a vision of future funding efforts in Parkinson's disease biomarkers.
MeSH terms
-
Biomarkers / analysis*
-
Biomarkers / blood
-
Biomarkers / cerebrospinal fluid
-
Carrier Proteins / genetics
-
Carrier Proteins / metabolism
-
Cytokines / metabolism
-
Glutathione / cerebrospinal fluid
-
Humans
-
Intracellular Signaling Peptides and Proteins / cerebrospinal fluid
-
Oncogene Proteins / cerebrospinal fluid
-
Parkinson Disease / diagnosis
-
Parkinson Disease / economics*
-
Parkinson Disease / therapy
-
Protein Deglycase DJ-1
-
Tumor Suppressor Proteins / genetics
-
Tumor Suppressor Proteins / metabolism
-
Uric Acid / blood
-
alpha-Synuclein / cerebrospinal fluid
-
tau Proteins / metabolism
Substances
-
Biomarkers
-
Carrier Proteins
-
Cytokines
-
Intracellular Signaling Peptides and Proteins
-
Oncogene Proteins
-
ST13 protein, human
-
Tumor Suppressor Proteins
-
alpha-Synuclein
-
tau Proteins
-
Uric Acid
-
PARK7 protein, human
-
Protein Deglycase DJ-1
-
Glutathione